Key facts
- It has raised $132.5M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($132.5M) in Apr 2024.
- 4 institutional filers report fund marks on Endeavor BioMedicines across 30 filings.
- Endeavor BioMedicines has filed 2 Form Ds with the SEC since 2022, most recently May 2024 ($132.6M sold to 32 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Endeavor BioMedicines
Create free account
No card required
Funding rounds
2 roundsApr 2024Later Stage VC (Series C)$132.5M▮
About Endeavor BioMedicines
- Industry
- Drug Discovery
PA Mark — not yet priced
Endeavor BioMedicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Endeavor BioMedicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
4 filers · latest Jun 20264 SEC-registered funds reported 30 fair-value marks on Endeavor BioMedicines between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.